LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

Authors:
  • CFC. Faivre-Finn
    C. Faivre-Finn
  • DVD. Vicente
    D. Vicente
  • TKT. Kurata
    T. Kurata
  • DPD. Planchard
    D. Planchard
  • LPL. Paz-Ares
    L. Paz-Ares
  • JVJ.F. Vansteenkiste
    J.F. Vansteenkiste
  • DSD.R. Spigel
    D.R. Spigel
  • MGM.C. Garassino
    M.C. Garassino
  • MRM. Reck
    M. Reck
  • SSS. Senan
    S. Senan
  • JNJ. Naidoo
    J. Naidoo
  • ARA. Rimner
    A. Rimner

Abstract
No abstract available
Funding Information
  • AstraZeneca